Tradestie Institutional Equity Comparison Engine

ATPC vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATPC Overall Edge

ATPC Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agape ATP Corporation Common Stock (ATPC) driven by superior Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, ATPC trades at N/M Forward P/E with -239.0% operating margin (-93.4% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ATPC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ATPC N/M vs CDT N/M Fwd P/E
Growth & Margin Winner CDT
Op Margin -239.0% vs 0.0% ยท YoY -93.4% vs +0.0%
Momentum & Technical Winner ATPC
1Y -8.7% vs -86.8% ยท 52W Pos 13% vs 2%
Options & Structure Winner ATPC
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
ATPC NASDAQ
Agape ATP Corporation Common Stock
Services-Health Services
$1.16
-15.94% 1D
Market Cap $1.4M
1M Return -18.31%
1Y Return -8.66%
Forward P/E N/M
Unified AI Score
51.6 / 100 HOLD
Tech 71.0 Fund 47.0 Flow 50.0 Mom 54.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ATPC -8.66% CDT -86.78% Spread: +76.01 pp (ATPC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ATPC TTM Op. Margin: -239.0% CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATPC vs CDT. Trailing 12-month operating profitability (ATPC -239.0% vs CDT 0.0%) and valuation multiples (ATPC N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ATPC (4) vs CDT (3)
Institutional Metric ATPC CDT Criterion Row Winner
Market Capitalization Scale $1.4M $507,528 Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -93.4% +0.0% Higher Growth CDT
Operating Margin (TTM) Profitability -239.0% 0.0% Higher Margin CDT
Net Profit Margin Profitability -86.3% 0.0% Higher Margin CDT
Return on Equity (ROE) Capital Efficiency -5.5% -69.7% Higher ROE ATPC
52-Week Range Position Momentum 13% ($0โ€“$8) 2% ($0โ€“$11) Stronger Trend ATPC
Beta / 30D Volatility Risk Regime 0.83ฮฒ ยท 135% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk ATPC
Unified Institutional Score Composite Signal 51.6 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite ATPC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ATPC vs CDT Buy Guide
ATPC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ATPC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ATPC nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.